Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Market Insight

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman

October 2025

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.

Last Week

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

7 Days: 1.2%
3 Months: 8.5%
1 Year: 17.7%
Year to Date: 14.8%

The market has climbed 1.2% in the last 7 days, lead by the Information Technology sector with a gain of 2.4%. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›

Editas Medicine, Inc. Stock Price

EDIT Share Price Performance

EDIT Community Narratives

Recent EDIT News & Updates

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Consensus revenue estimates increase by 35%, EPS downgraded

New minor risk - Financial position

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables in Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia At the European Hematology Association 2025 Congress in June

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Consensus revenue estimates increase by 17%, EPS downgraded

Editas Medicine, Inc. Reports New in Vivo Proof of Concept Data in an Undisclosed Liver Target At the American Society of Gene and Cell Therapy Annual Meeting

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Editas Medicine, Inc. to Report Q1, 2025 Results on May 12, 2025

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine, Inc. Key Details

Editas Medicine, Inc. Competitors

Snowflake Analysis

About EDIT

Market Insight

✨Rare Earths: Tiny Market, Outsized Influence

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance